Acetylcholinesterase inhibitors and nanoparticles on Alzheimer's disease: a review

S Silva, AJ Almeida, N Vale - Journal of Nanoparticle Research, 2021 - Springer
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease clinically
characterized by progressive loss of memory, impairment cognitive function, and …

Therapeutic strategies and nano-drug delivery applications in management of aging Alzheimer's Disease

TT Nguyen, TK Vo, GV Vo - Reviews on New Drug Targets in Age-Related …, 2021 - Springer
Alzheimer's disease (AD) is a neurodegenerative disorder in which the death of brain cells
causes memory loss and cognitive decline. Existing drugs only suppress symptoms or delay …

Advanced nanoparticular approaches to combat Alzheimer's disease

R Shah, S Bhattacharya - Pharmaceutical Nanotechnology, 2021 - ingentaconnect.com
Alzheimer's disease (AD) is a neurological disease that affects many of the world's rapidly
ageing population. In the etiology of Alzheimer's disease (AD), the involvement of amyloid β …

Nanoparticles for the potential treatment of Alzheimer's disease: A physiopathological approach

N Navarro Martínez, J Toledo Hernández… - Nanotechnology …, 2023 - degruyter.com
Alzheimer's disease (AD) is a multifactorial neurodegenerative central system disease with a
high prevalence among the elderly and is the most common form of dementia. Oxidative …

Alzheimer's disease targeted nano-based drug delivery systems

G Altinoglu, T Adali - Current Drug Targets, 2020 - ingentaconnect.com
Alzheimer's disease (AD) is the most common neurodegenerative disease, and is part of a
massive and growing health care burden that is destroying the cognitive function of more …

Nanoparticle-mediated approaches for Alzheimer's disease pathogenesis, diagnosis, and therapeutics

SD Hettiarachchi, Y Zhou, E Seven… - Journal of controlled …, 2019 - Elsevier
Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder
manifested by memory loss and cognitive impairment. Deposition of the amyloid β plaques …

[HTML][HTML] Advances in developing therapeutic strategies for Alzheimer's disease

TT Nguyen, TTD Nguyen, TKO Nguyen, TK Vo - Biomedicine & …, 2021 - Elsevier
Alzheimer's disease (AD) is a progressive deterioration of brain function, initially
characterized by cognitive deficits, with loss of recent memory and language ability …

Multifunctional nanocarriers for Alzheimer's disease: befriending the barriers

MA Ansari, T Tripathi, B Venkidasamy, A Monziani… - Molecular …, 2024 - Springer
Neurodegenerative diseases (NDDs) have been increasing in incidence in recent years and
are now widespread worldwide. Neuronal death is defined as the progressive loss of …

Research progress of nanocarriers for the treatment of Alzheimer's Disease

L Li, J Zhang, X Huang, J Du, Z Tu, H Wu… - Current …, 2023 - ingentaconnect.com
Currently, many therapeutic drugs are difficult to cross the blood-brain barrier (BBB), making
it difficult to reach the site of action and thus fail to achieve the desired efficacy. In recent …

Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer's disease

P Namdeo, J Mathew, A Garg - Nanomedical Drug Delivery for …, 2022 - Elsevier
The overall incidental rate for neurodegenerative illnesses has risen in conjunction with the
aging population nowadays. Defects in beta-amyloid (Ab) and cholinergic system deposition …